Press Releases & News


July 2019

Research Collaboration and License Agreement with Genentech

Clover Therapeutics has entered into a research collaboration and license agreement with Genentech, a member of the Roche Group, to better understand the genomic factors that increase an individual’s risk for developing ocular diseases.


July 2019

A Patient Driven Therapeutics Company

Cheng Zhang, Head of Clover Therapeutics, explains our vision for building a patient-driven research community and its importance.

Leveraging Disease Complexity and Patient Diversity for Drug Discovery

Marcel van der Brug, Chief Scientific Officer of Clover Therapeutics, describes our scientific approach to accelerating the development of innovative medicines for diseases of aging.

For all media inquiries, please contact